Stocks losers - Yahoo Finance
- AZN.LMotley Fool•12 hours ago
AstraZeneca, Bristol-Myers Squibb, and Pfizer receive good news from the real world.
- AZN.LMotley Fool•17 hours ago
Although niraparib's approval seemed imminent, the broad label is far better than expected.
- AZN.LReuters - UK Focus•21 hours ago
** AstraZeneca off 0.5% after Tesaro wins U.S. approval for ovarian cancer drug Zejula , a rival so-called PARP inhibitor to UK firm's Lynparza ** Zejula also wins approval for broader use in women than ...